Genetics of Alzheimer's Disease with Julie Williams: Microglia, Immune Pathways and Precision Medicine

Overview

The podcast features a conversation with Julie Williams, a world leading authority on the genetics of Alzheimer’s disease. The discussion spans the historical understanding of Alzheimer’s, how genetic studies are guiding biology, and the potential for precision medicine to tailor prevention and treatment.

• Genetics as a driver of understanding Alzheimer’s disease biology
• The rise of genome wide association studies and immune pathways
• Role of microglia and complement system in neurodegeneration
• Implications for risk prediction and future therapies

Introduction and the scientist behind the work

The podcast opens with an introduction to Julie Williams, a leading figure in neuropsychological genetics. Born in Wales in 1957, Williams has shaped research into how genes influence psychological and neurodegenerative disorders, notably Alzheimer’s disease. She has also served as chief scientific advisor to the Welsh government and now directs a dementia research centre in Cardiff. The host frames the discussion around what we mean by Alzheimer’s disease and how its development begins long before clinical symptoms appear.

From curiosity to genetics

Williams recounts her early curiosity about how the brain works and how she moved from psychology into biology and genetics. She describes the historical context when her career began, including rare families with early onset Alzheimer’s disease and high heritability, which hinted at genetic contributions. The challenge at that time was limited tools for genome exploration, making the process slow and sample-hungry. Williams explains the shift from studying single genes to interrogating hundreds of thousands of genetic markers across the genome to identify regions associated with disease.

Genome wide association studies and the immune system

A central theme is how large-scale genetic studies revealed surprising connections to the immune system. Williams explains that early neuropathology showed glia and immune activity in the diseased brain, but genetics began to frame these as causal pathways rather than reactive responses. The discussion highlights the importance of collecting large, representative samples across the UK to power these analyses, as well as sequencing cost reductions and methodological advances that enabled genome-wide scans.

Microglia, complement system and disease mechanisms

The conversation emphasizes that many risk genes for Alzheimer’s are expressed in microglia, the brain’s resident immune cells. Williams notes that this points to inflammation and immune regulation as central components of the disease mechanism, not just downstream effects. The complement system, a key part of innate immunity, emerges as a potential therapeutic target, with implications for how drugs might be delivered to the brain and how patient risk profiles could guide treatment choices.

Genetics, risk prediction and precision medicine

The host and Williams discuss how genetic data are used to stratify risk on a population basis and how predictive models combine many genes to identify individuals at high risk. Williams stresses that while predictive tools are powerful, their real value will be realized when matched with effective therapies. She foresees a future where genetic information informs prevention strategies and drug choices for the most at-risk individuals, while environmental and lifestyle factors explain risk for others.

Therapies, gene editing and the Huntington’s example

The discussion covers potential therapeutic avenues including immune-modifying drugs and drugs targeting the complement pathway. Williams also mentions gene therapy approaches in Huntington’s disease as a proof of concept for delivering genetic interventions to the brain. The conversation points to ongoing work that uses cell models to study how risk genes affect cellular function and how cutting-edge techniques like CRISPR might be harnessed for disease modification.

Policy, science funding and media engagement

Beyond the lab, Williams reflects on her time as Wales’ chief scientific adviser, the importance of investing in science capacity, and building momentum around dementia research. The interview ends with thoughts on making science more accessible through media and the need for ongoing dialogue between scientists and policymakers to translate genetic insights into real-world health benefits.